Abstract Purpose: Aberrant DNA methylation, now recognized as a contributing factor to neoplasia, often shows definitive gene/sequence preferences unique to specific cancer types. Correspondingly, distinct combinations of methylated loci can function as biomarkers for numerous clinical correlates of ovarian and other cancers. Experimental Design:We used a microarray approach to identify methylated loci prognostic for reduced progression-free survival (PFS) in advanced ovarian cancer patients.Two data set classification algorithms, Significance Analysis of Microarray and Prediction Analysis of Microarray, successfully identified 220 candidate PFS-discriminatory methylated loci. Of those, 112 were found capable of predicting PFS with 95% accuracy, by Prediction Analysis of Microarray, using an independent set of 40 advanced ovarian tumors (from 20 short-PFS and 20 long-PFS patients, respectively). Additionally, we showed the use of these predictive loci using two bioinformatics machine-learning algorithms, Support Vector Machine and Multilayer Perceptron. Conclusion: In this report, we show that highly prognostic DNA methylation biomarkers can be successfully identified and characterized, using previously unused, rigorous classifying algorithms. Such ovarian cancer biomarkers represent a promising approach for the assessment and management of this devastating disease.
Consequently, identification of specific methylated CpG islands, as biomarkers for distinct cancer types, holds potential for diagnosis and monitoring of disease progression. In rare cases, methylation of single loci is prognostic for specific cancer types. For example, methylation of GSTP1 has been shown as a highly specific marker for prostate cancer (2, 3) . In most cases, however, methylation of single genes is not specific enough to be used for screening of large populations, and several groups are now focusing on establishing panels of methylated markers possessing greater disease sensitivity and specificity. To that end, House et al. (4) showed that panels of methylated genes were more predictive than single genes for the prognosis of pancreatic, hepatocellular (5) , and gastrointestinal (6) neoplasms. In a pilot feasibility study of ovarian cancer, we recently identified candidate loci that significantly correlated with progression-free survival (PFS, the time period between chemotherapy initiation and tumor relapse) in patients with advanced-stage disease (7) . That study and others show that distinct methylated loci may serve as tumor biomarkers.
As many reports now suggest that DNA methylation is not stochastic, as previously proposed (1) , but may actually exhibit tumor/stage -specific patterns (8), we endeavored to determine a ''methylation signature'' for predicting ovarian cancer PFS. In the present study, we subjected methylation microarray results to two recently described biostatistical analyses, Prediction Analysis of Microarray (PAM) and Significance Analysis of Microarray (SAM; refs. 9, 10), to identify a set of potential PFSdiscriminatory loci. Those loci were then further examined using a cohort of 40 ovarian tumors, successfully predicting PFS with 95% accuracy. Finally, using two machine-learning algorithms [Support Vector Machine (SVM) and Multilayer Perceptron (MLP)], we further showed the use of those loci.
Such clinically correlated methylated loci could serve as valuable biomarkers having broad prognostic and therapeutic applications.
Materials and Methods
Tissues and DNA specimens. Forty advanced-stage epithelial ovarian tumors and seven normal adjacent ovarian tissues were obtained from the Cooperative Human Tissue Network (Columbus, OH), Western Infirmary and Stobhill General Hospital (Glasgow, United Kingdom), and Cedar-Sinai Medical Center (Los Angeles, CA), following pathologist examination and classification. PFS was defined as the time to progression from start of treatment. All patients were treated with carboplatin-or cisplatin-based chemotherapy and most included a taxoid. Clinicopathologic information for the samples is listed in Table 1 . All studies were approved by local institutional review boards.
Differential methylation hybridization. Differential methylation hybridization was done as we have described previously (7, 11) . Briefly, genomic DNA was digested using MseI, before ligation to end-linkers and subsequent restriction with the methylation-sensitive endonucleases BstUI and HpaII, followed by PCR from end-linker primers. PCR-amplified products thus represented pools of methylated (restriction-resistant) species, as unmethylated species were digested. The purified amplicons were then aminoallyl-UTP labeled, coupled with either Cy5 (cancer amplicons) or Cy3 (normal reference amplicons), hybridized to the microarray, washed, and scanned (7, 11) . Subpanels of specific loci, derived from extensive analyses of our previous (7,776 loci) microarray results (7), were printed on aminosilane-coated slides, using an Affymetrix/GMS 417 arrayer. For the first subpanel, 220 loci were printed for (single dye) hybridization, using a cohort of nine tumors. For the second subpanel, 112 (significantly identified subset of the 220) sequences were printed and hybridized to DNA from the 40 tumors and 7 normal tissues described above, using lymphocyte DNA as the cohybridization (normal) reference. Thus, for the 112-feature subpanel, both Cy5-labeled (tumor) and Cy3-labeled (normal) DNA were used, with Cy5/Cy3 fluorescence ratios subsequently determined to assess DNA hypermethylation, of specific loci, in tumors. III  PD adenocarcinoma  7  O98  III  PD  14  O86  IIIC  MD  7  12T  IIIC  SP, adenocarcinoma  60  O37  IV  NA  4  O44  IV  SP, adenocarcinoma  20  AN2  IIIA  SP, adenocarcinoma  NA  26T  IV  SP, adenocarcinoma  39  20T  IIIC  SP, adenocarcinoma  4  O100  IV  MD  12  O99  III  SP, PD  (8)  O56  IIIC  PD  16  O8  III  MGC  (6)  AN3 Data acquisition and normalization. Hybridization signal images were analyzed for spot intensities using a GenePix 4000A (Axon Instruments, Union City, CA) scanner. For each spot, the median Cy5/ Cy3 ratio represented the index of methylation difference between tumor and normal amplicons. To correct for variations in hybridization signals, the Cy5/Cy3 intensities were normalized as we have described previously (7, 11) .
SAM and PAM analyses. From our previous differential methylation hybridization study, eight patient tumors with high methylation versus 11 samples with low methylation correlated significantly with short versus long PFS, respectively (7). To identify distinct, differentially methylated loci, SAM analysis (10) was used to determine loci displaying different methylation levels between ovarian cancer patient groups with short and long PFS. SAM can select genes with a prespecified false discovery rate (10) and can rank loci based on their scores rather than on changes in methylation. SAM analysis of the logtransformed microarray data set ''scored'' each locus by statistically determining a methylation ratio difference between the two tumor groups. The SAM score is an extension of a t test statistic, which can penalize unstable, low hybridization signals produced by microarray technologies. SAM analysis requires statistical distribution assumptions of the methylation data for constructing a score (i.e., the first two moments are finite and the distribution is symmetric). However, these assumptions are not necessary for the Wilcoxon test rank sum test, which tends to be more stringent and robust in selecting candidate loci (12) . Therefore, to further screen SAM-identified loci having significant (P < 0.05) methylation differences between group 1 and group 2 tumors, a Wilcoxon nonparametric rank sum test (12) in SPlus was applied, excluding missing values. Thus, we implemented both SAM and Wilcoxon tests.
PAM (9) is a statistical analysis that selects an optimal list of loci and their linear combination in such a way that its prediction accuracy of clinical outcome (long or short PFS in this case) is maximized by 10-fold cross-validation. PAM analysis is also a ''shrinkage'' method, which can shrink coefficients of some loci to zero, when constructing their linear combination. Thus, it is a highly effective way of eliminating less informative loci to arrive at an optimal prediction accuracy. For PAM evaluation, shrunken centroid analysis (9) was used to average methylation values for each locus to derive a ''centroid'' for the group and ''denoise'' the group centroids by shrinkage toward zero, the overall centroid for the specimens examined (9) . This approach, normalized by within-class SDs for each locus, effectively assigns higher weights to loci with stable (within the same group) methylation ratios. PAM implemented a threshold variable across iterative shrinkage increases, using 10-fold cross-validation to determine class prediction errors. Prediction accuracy was balanced by the smallest set of loci required for the final model at each shrinkage threshold.
Machine learning schemes. Classification algorithms were from Weka (13), a collection of machine learning tools. 10 For machine learning, PFS-discriminatory loci were used to build classifiers using SVM (14) and MLP (15) as described in Results. SVM is a tool that optimizes ''generalization,'' referring to the ability to correctly categorize unseen data (14) . The SVM algorithm operates by mapping the given training set (''input vectors'') into a high-dimensional feature space and attempting to locate in that space a plane that optimally separates the positive from the negative examples, with a minimum classification error for unseen samples (14) . MLP is an algorithm that uses simulated neurons (''perceptrons'') connected by networks that constitute several ''layers.'' A typical MLP network consists of a set of source neurons (equal in number to the number of variables of the problem) forming the input layer, one or more hidden layers of computation nodes, and an output layer of nodes (15) . The input signal disseminates throughout the network from the input to hidden to output layers.
False discovery rate estimation. False discovery refers to the expected proportion of false-positive findings among all rejected null hypotheses (i.e., those features that are statistically significant). In our analyses, the null hypothesis was that loci would display no difference in methylation between long-and short-PFS tumors. The direct approach proposed by Storey (16) was used to estimate false discovery rate for selected significant features.
Results
Identification of methylated biomarkers for predicting PFS. We used two recently developed data set classification methods, SAM (10) and PAM (9) , to identify loci significantly correlated with shortened PFS. Previously, we segregated 19 tumors (Table  1 , test set 1) from advanced ovarian cancer patients into highand low-methylation classes (7), with highly methylated tumors correlating significantly with reduced patient PFS (6-month median) and less methylated tumors associating 10 www.cs.waikato.ac.nz/ml/weka/. Fig. 1 . Schematic diagram of this study. Our previous differential methylation hybridization analysis of advanced ovarian carcinomas, using a 7,776 CGI microarray, yielded 811CGI loci hypermethylated in at least 3 of 19 tumors (7). SAM, applied to these 811CGI loci, yielded 329 CGI loci displaying significant (P < 0.05)
differences. Further refinement (of the 329 CGI), using a two-sided Wilcoxon t test, yielded 270 CGI differentially methylated (P < 0.05) in group 1versus group 2 (short versus long PFS; see text for details). In addition, PAM was also applied to the 811candidates. SAM and PAM analyses were combined with loci previously identified by hierarchical clustering and batch sequential forward selection to arrive at 220 CGI for subsequent printing on a subpanel differential methylation hybridization microarray. That panel was then used to analyze nine advanced ovarian tumors, yielding 112 hypermethylated CGI. A second subpanel microarray, constructed from the 112 CGI, was analyzed by differential methylation hybridization using an independent, additional test set consisting of 40 advanced ovarian tumors (20 short and 20 long PFS, groups 1and 2), yielding 95% classification accuracy between the two groups (bottom right). To further evaluate the 112 loci, we used those markers to construct two separate classifiers, using the algorithms MLP and SVM; both showed 100% classification accuracy. See text for details. BSFS, batch sequential forward selection. with longer (>12 months) PFS. Specifically, from a total of 7,776 CpG islands, 182 methylated loci were identified to classify reduced PFS using hierarchical clustering and batch sequential forward selection (7). In the current study, we endeavored to validate those predictive loci and perhaps discover additional putative biomarkers, using SAM and PAM. Although both of these algorithms have previously been applied to gene expression microarrays (9, 10) , to our knowledge, this is the first use of these methods for highthroughput methylation analyses. For SAM analysis, a ''supervised'' technique used to correlate microarray results with clinical variables, 811 CpG island loci (CGI; from the total of 7,776) were found methylated in at least 3 of 19 advanced-stage tumors (Fig. 1) . SAM analysis showed significant (P < 0.05) differences in methylation, between short-PFS (group 1) and long-PFS (group 2) tumors, for 329 of those loci ( Fig. 2A) , with an estimated false discovery rate of 0.88% (data not shown). As SAM analysis makes statistical distribution assumptions (i.e., the first two moments are finite and the distribution is symmetric), we used a two-sided Wilcoxon t test, a method that does not require distribution assumptions for data (12) , to analyze the 329 loci. The Wilcoxon analysis identified 270 loci possessing significantly greater (P < 0.05) methylation in group 1 versus group 2 tumors. Of the 270 total loci, 107 overlapped with those identified previously by batch sequential forward selection (of the previous total of 182; ref. 7) .
To further evaluate the SAM/Wilcoxon -validated PFS markers, PAM analysis of the 270 loci (the SAM/Wilcoxon subset) was done. The PAM algorithm involves minimization of a set of genes that characterize a specific classification (in this case, PFS; ref. 9). Here, the average methylation levels (''centroids'') of PFS-related genes were reduced (''shrunk''), by increasing threshold values, to decrease the number of discriminative genes. At each shrunken threshold value, misclassification was then determined by 10-fold cross-validation, a standard verification technique that divides the data into 10 approximately equal partitions. Each partition is then, in turn, used for testing, whereas the others are used for training (i.e., 90% of the data used for training and 10% for testing), with the whole procedure repeated 10 times (17) . As shown in Fig. 2B , PAM analysis resulted in highly divergent centroids, of the 270 loci, between the two survival groups. These centroids could be reduced at a threshold value of 2.2, with no corresponding increase in misclassification error (Fig. 2C) ; however, the accuracy of this subset was only 62.5% (Fig. 2C , Y axis), with three of eight group 1 tumors misclassified ( Fig.  2D and E) . Thus, the total of 270 was not further reduced by this analysis. PAM was also applied to the original test set (811 loci), resulting in the identification of 141 significant features; those were, however, no more discriminatory than the SAMidentified 270 (data not shown).
To improve prediction accuracy, we selected 220 of the most promising loci by combining sequences from (a) our previous study (using batch sequential forward selection; ref. 7), (b) those identified by SAM/Wilcoxon, and (c) those identified by PAM (Fig. 1) . Those criteria were balanced by technical issues, including the use of clones that were readily extractable from libraries and those providing PCR products suitable for printing. Following selection, the 220 candidate loci were printed (in triplicate) on arrays. Differential methylation hybridization, an array-based technique capable of examining >7,000 methylated sequences simultaneously (11), was then done using (single-dye) labeled DNA from nine advanced ovarian tumors; of the 220 loci, 112 showed significant hybridization (a list of 40 known genes within this panel is provided in Table 2 ). Subsequently, these 112 loci were printed on slides and hybridized to genomic DNA from 20 advanced ovarian tumors from patients with short PFS (median 6 months, group 1; Fig. 3A , solid line), 20 tumors from patients with long PFS (median 22 months, group 2; Fig. 3A , dotted line), and 7 normal tissues (Table 1, test set 2). After normalization of the data (Fig. 3B) , PAM was used to ascribe loci distinct to group 1 (thus correlated with short PFS). As shown in Fig. 3C , a clear divergence in methylation levels, at specific CpG islands, was observed between the PFS groups. Moreover, further attempts to reduce the number of discriminatory loci (i.e., increase the ''shrinkage'' threshold) resulted in greatly increased misclassification (Fig. 3D) , indicating that these 112 loci were highly class-selective. Overall, the accuracy probabilities of these 40 tumors were estimated at >80% for both groups 1 and 2 (Fig. 3E) . As shown, group assignment predictions, using shrunken centroid analysis, were clearly enhanced for the 112-loci panel, yielding reduced misclassification rates (1 of 20, thus 95% accurate) for both PFS groups (Table 3) . For further study of our biomarker panel, we evaluated the 112 loci using various statistical and bioinformatics analyses. Classification models were constructed from the entire 112-loci PFS-predictive panel, using SVM and MLP (Weka, see Materials and Methods). The input variable to these algorithms was a twodimensional matrix representing methylation values of 112 individual loci within each of the 40 (20 short-and 20 long-PFS patient) tumors previously examined by PAM. Both of these methods showed 100% classification accuracy, as assessed by 10-fold cross-validation (see Table 3 ). That accuracy (100%), using these alternative algorithms, was similar to the accuracy achieved by PAM (95%); such a similarity would be entirely expected, as PAM had previously optimized the most useful discriminatory features. To determine the false discovery rate (the number of discriminatory loci possibly discovered by chance), we used the direct approach of Storey (16) . In total, methylation levels of all 112 loci were compared (based on t test) between the short and long PFS groups, resulting in a determination that only 25% (28 loci) could be due to chance. Therefore, the majority (84 loci or 75% of the total) of the panel would yet possess differential methylation; however, without further validation, we cannot predict which specific loci are hypermethylated. Consequently, we contend that the high-PFS prediction accuracy (95%) from this panel is not merely due to a random set of loci; rather, the majority of the loci indeed possess differential methylation between the two groups.
Discussion
In the present study, we used two recently developed microarray analysis algorithms, SAM (10) and PAM (9) , to screen methylated loci associated with PFS in ovarian cancer. By combining SAM and PAM with the results of our previous pilot study (7), we identified 220 PFS-discriminatory candidate loci. Further screening and experimental analysis resulted in the identification of 112 highly discriminatory loci possessing a PFS prediction accuracy of 95% ( Fig. 1; Table 3 ). We believe that this type of approach is highly amenable to the study of other cancers, as methylation patterns have previously been suggested as tumor and stage specific (8) .
To supplement traditional cancer prognosis methods, such as that examining tumor size, lymph node presence, and metastasis (i.e., the classic ''tumor-node-metastasis'' staging system), biomarkers are now emerging as highly informative for monitoring disease status (18) . Such markers can be DNA sequences (e.g., single-nucleotide polymorphisms, deletions), mRNA, or proteins/peptides (18) . Epigenetically modified DNA, however, offers potential advantages over other markers, in that it is well associated with tumor progression and several sensitive, high-throughput assays are now widely available (19) . DNA is also more stable than RNA, and methylation biomarkers have been established as present in patient serum and other body fluids (20) .
To date, several methylated genes have been found highly prognostic for specific cancers, including prostate (21), breast (22) , and lung (23) . Although some methylated markers, such as RASSF1A and GSTP1, hold potential as prognostic indicators individually (2, 3, 24) , it seems that panels (''methylation signatures'') will be much more informative (25) and accurate for monitoring cancer progression. Indeed, such predictive panels have previously been shown using expression microarrays. In one study of epithelial ovarian cancer, an ''expression signature'' of 115 genes was described as prognostic for overall survival (26) . Similarly, an 11-gene expression panel, corresponding to a pathway involving the putative stem cell renewal protein Bmi-1, was found associated with shortened PFS and distant metastasis in 10 different malignancies (27) . However, methylation signatures may offer advantages over expression signatures, for reasons described above. Additionally, methylated DNA has been shown as present in serum (20, 28) ; it will thus be important to determine whether any of our markers might also be present in body fluids and could thus be used to monitor disease status noninvasively.
To further screen our 112-loci panel for predictive ability, additional testing will be required in an independent prospective study, a validation trial where tumors have not been selected for high-and low-survival classes (i.e., tumors were analyzed and patients were followed over time). Although such a study would require several years, only randomized trials could conclusively determine the predictive value of this panel for response to chemotherapy.
In addition to serving as clinical biomarkers, discovery of specific methylated genes in ovarian cancer could, with further investigation, provide a greater understanding of cellular pathways and/or signals related to disease progression. DNA methylation frequently characterizes a repressive chromatin structure and methylation of specific genes can lead to downregulation of distinct biochemical pathways. Previous examples of independently discovered methylated genes include PTPRO (29), encoding a tyrosine phosphatase receptor, and a homeobox gene, ALX3 (30). Within our panel, the gene WWOX (Table 2) was previously shown to be involved in breast, lung, and bladder cancer progression (31) . In epithelial ovarian cancer, WWOX mRNA is significantly lower than in normal ovaries (32) , suggesting its role as a tumor suppressor. Based on our study, WWOX suppression is likely due to promoter methylation, as previously shown for breast, lung, and bladder neoplasms (31) . Similarly, ATOX1 (Table 2) , a homologue of a yeast antioxidant protein (33) , might play a role in protection from reactive oxygen species. This protein has been found to up-regulate an extracellular superoxide dismutase (SOD-3), by chaperoning copper ions required for SOD-3 activity (33). Thus, methylation and transcriptional repression of ATOX1 could potentially reduce reactive oxygen detoxification, which seems critical for prevention of cellular damage that often occurs in tumor progression (34) . In summary, to our knowledge, this is the first study reporting the use of two highly precise classification algorithms, PAM and SAM, for the identification of prognostic panels of DNA methylation cancer biomarkers. We believe that this approach is amenable to classification of clinically relevant methylation patterns in a wide variety of tumors (and other pathologies), potentially allowing improved management of numerous diseases linked with aberrant DNA methylation. 
